BioStock: Promore Pharma aims to accelerate healing of venous leg ulcers

Peptide company Promore Pharma is undeniably in an exciting phase with two drug candidates in the field of wound treatment currently in late clinical development, ensereptide and ropocamptide. BioStock has previously taken a closer look at ensereptide, which is now undergoing a phase IIa study, and today we are placing the spotlight on ropocamptide, which is being prepared for a coming phase III study. We took the opportunity to ask CEO Jonas Ekblom a few questions to find out more.

Read the whole interview with Promore Pharma's CEO Jonas Ekblom at biostock.se:

https://www.biostock.se/en/2022/05/promore-pharma-aims-to-accelerate-healing-of-venous-leg-ulcers/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se